Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab ; volume:19 ; number:1 ; day:28 ; month:10 ; year:2023 ; pages:1-4 ; date:12.2023
Allergy, asthma and clinical immunology ; 19, Heft 1 (28.10.2023), 1-4, 12.2023
- Classification
-
Medizin, Gesundheit
- Creator
-
Lopez, Michael
Hagopian, Garo
Doan, Linda
Lee, Benjamin J.
Rojek, Nathan W.
Smith, Janellen
Ou, Sai-Hong
Demirdag, Yesim Yilmaz
Nagasaka, Misako
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13223-023-00849-5
- URN
-
urn:nbn:de:101:1-2024011608304170969430
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lopez, Michael
- Hagopian, Garo
- Doan, Linda
- Lee, Benjamin J.
- Rojek, Nathan W.
- Smith, Janellen
- Ou, Sai-Hong
- Demirdag, Yesim Yilmaz
- Nagasaka, Misako
- SpringerLink (Online service)
Other Objects (12)
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Editorial-T790M mutation and clinical outcomes with genuine osimertinib
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Editorial-T790M mutation and clinical outcomes with genuine osimertinib
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Editorial-T790M mutation and clinical outcomes with genuine osimertinib
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V